RxDoctor Payments Data

Mark Schlotterback, MD

Family Medicine · Gilbert, AZNPI 1861449944

Payments from drug & device makers

$9,155in general payments, 2019–2025

Across 574 payments — averaging $15.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$940
  • Lilly USA, LLC$718
  • GSK$603
  • Novo Nordisk$592
  • Amgen$566
  • plus $4K from 51 others

What the payments were for

  • Food & beverage$9,10499%
  • Education$511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,155 in reported general payments places this provider in the 90th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$395,855
Medicare patients
1,035
Services billed
12,079

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban51$78,608
OzempicSemaglutide53$70,737
FarxigaDapagliflozin Propanediol49$54,879
JardianceEmpagliflozin25$36,055
TrulicityDulaglutide24$29,290
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$25,630
Soliqua 100-33Insulin Glargine/Lixisenatide34$25,132
MounjaroTirzepatide20$24,640
GlyxambiEmpagliflozin/Linagliptin25$22,882
Repatha SureclickEvolocumab31$21,837
XareltoRivaroxaban25$21,267
Felbamate13$10,713
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$6,363
SymbicortBudesonide/Formoterol Fumarate15$6,295
Breo ElliptaFluticasone/Vilanterol14$6,264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$540$78,60851 claims
Novo NordiskOzempic$592$70,73753 claims
Boehringer IngelheimJardiance, Glyxambi, Synjardy Xr$389$64,78462 claims
AstraZenecaFarxiga, Symbicort$940$61,17464 claims
Lilly USA, LLCTrulicity, Mounjaro$718$53,93044 claims
GSKTrelegy Ellipta, Breo Ellipta$603$31,89442 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$190$25,13234 claims
Johnson & JohnsonXarelto$165$21,26725 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$193$3,53012 claims
Hikma Pharmaceuticals USABuprenorphine$12$3,05512 claims
AbbVieSynthroid$1,447$2,32827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Gilbert

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →